In this episode of the Merge Medical Deep Dive Podcast, Drs. Jeff Brown and Jeff Cole speak with Rob Bohacs, Founder and CEO of Researchify Health.Researchify Health is a revenue-stage AI company transforming clinical trial recruitment and patient engagement. Generating $900K in SaaS revenue in 2025, with a projected ARR of $1.3M by the end of next year, the company leverages AI-driven, SMS-based communication to streamline patient pre-screening, scheduling, and ongoing trial updates.Researchify Health’s platform accelerates clinical trial participation, simplifies scheduling, and drives higher engagement through consistent follow-ups and AI study matching. This streamlined process guides patients seamlessly through their clinical trial journey, helping to bring drugs to market more rapidly.Founded by seasoned clinical trial entrepreneurs with two prior exits, Researchify Health addresses key pain points in clinical trial enrollment. With a track record of innovation, the company is poised to become a leading AI platform in clinical trial engagement. A visual overview of their solution can be found here: https://youtu.be/G3FQI-cic0EInvestment and Strategic Partner Opportunities:Researchify Health has been founder-funded and is now seeking its first external capital raise of $800K through a convertible note, structured with a 5% annual interest rate, a 10% discount, and a $6.5M cap.*****Would this bring value to you, your family or your medical practice? Investable merits of this company? Let’s discuss in the forum.If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion.Sign up today!https://mergemedical.community.forum/ *****DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

Take the demo for a spin. It’s set up as a dentistry practice, so you can role-play scheduling an appointment. Challenge the AI by asking tough questions or even making inappropriate statements—things that would test your best staff members. You’ll be amazed by its professionalism, natural voice inflections, and overall performance.Demo Link (6 min full demo)or Demo call line: 928-492-5907And there’s more to it than just that.In this episode of the Merge Medical Deep Dive Podcast, Drs. Jeff Brown and Jeff Cole speak with Rahul Sharma, co-founder and CEO of Neurality Health.Neurality Health AI streamlines the administrative and operational tasks of both the front and back office using human-like voice and text. The AI handles inbound calls, schedules appointments, educates patients, and enhances engagement through recall and reactivation programs. It also verifies insurance benefits, manages payer communications, and has the potential to take on other revenue cycle management (RCM) responsibilities.Neurality Health’s onboarding process also includes several proprietary and AI-enhanced processes allowing them to add pilot practices and paying customers quickly and with ease. Their sales are reaching an inflection point where some might even say they are “exploding” to the upside. The company is rapidly expanding from its initial focus on dentistry into multiple medical subspecialties.Founded by seasoned health tech entrepreneurs and AI experts, Neurality Health is addressing key pain points faced by clinicians. With a track record of success and a focus on continued innovation, Neurality Health is poised to become the AI operating system of the future for healthcare.Investment and strategic partner opportunities:Neurality Health quickly closed a $350K pre-seed round largely funded by subject matter experts and customers within their initial target market of dentistry. They have opened an add-on pre-seed round also structured as a Y-Combinator SAFE note at a compelling valuation of $5M. Strategic partners and investors have been identified within several medical specialties such as ENT and orthopedic surgery. This offering is capped at $500K and may be filled by the time of this publication.*****Would this bring value to you or your medical practice? Investable merits of this company? Let’s discuss in the forum.If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today!https://mergemedical.community.forum/*****DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

Here’s the thing about patient care – the caring never stops. Patients and their healthcare providers have questions, and answers just can’t wait. To find these answers, healthcare professionals “run cases by each other”. These casual “curbside” consultations are vital to improve access to specialty expertise.Join Drs Jeff Brown and Jeff Cole in the “Deep Dive” version of the Merge Medical podcast as they interview Dr. Richard Popwell, CEO and Founder of DocSide.There was a time when a much higher density of physicians would cross paths in the physician’s lounge, surgery lounge or cafeteria of the typical hospital. Curbside consults have always been part of the culture of medicine, but times have changed. A large percentage of physicians and healthcare providers are now working in outpatient clinics and/or outpatient surgery centers. Sub-specialists simply don’t cross paths the way they they did 20 or 30 years ago.Curbsides aren’t always so easy. . . From finding the right expert, playing phone tag, interrupting each other’s work and family life. . . What’s meant to save time and effort does anything but…So, what if there was a way to simplify collaboration between healthcare professionals and facilitate safe, high quality, and equitable care for any patient, anywhere, anytime?Welcome to the DocSide! DocSide is an intuitive mobile and web-based solution that creates more equitable access, reduces costs, and optimizes care by empowering healthcare professionals with seamless curbside collaboration, shared documentation, and revenue generation. DocSide is more than just another healthcare app. It’s a place . . .Where a GP in rural America can consult with specialists in a large, urban medical center.Where patients don’t always have to drive to another appointment to get the care they need.Where curbsides create access and improve care with just the right amount of simple documentation.Where care is customized and outcomes optimized because over 3 million healthcare professionals can better serve 300 million potential patients.Where your time and expertise are rewarded both personally and financially.And, instead of burning out . . . there’s helping out.Welcome to the DocSide!Where curbsides are more connected.To learn more about DocSide, including potential investment opportunities, visit www.docsideapp.comemail [email protected] call 406-224-5297.*****Would this bring value to you, your family or your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion.Sign up today! https://mergemedical.community.forum/*****DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

Have founder Kenneth A. Levey, MD, MPH and the team at Mother Goose Health developed a multimodal approach that significantly reduces preterm birth? Join Drs Jeff Brown and Jeff Cole in the “Deep Dive” version of the Merge Medical podcast as they interview Shelle’ Jones and Dr. Ken Levey, CEO and Founder of Mother Goose Health. Mother Goose Health is a maternity care management company that better supports patients and providers in achieving optimal maternal and infant health outcomes by unifying the maternity care ecosystem within a single platform. Through seamless integrations, the Mother Goose Health platform improves care coordination while also reducing provider workload through care management and support. Targeted, proprietary risk-detection algorithms identify rising risk which allows proactive care. Kenneth A. Levey, MD, MPH is a board-certified obstetrician-gynecologist, and the founder of New York City’s largest independently owned Women’s Health practice. Dr. Levey has launched several healthcare technology companies aimed at better supporting the patient-provider dyad, including his latest Mother Goose Health. Mother Goose Health’s provider-patient focus has proven ability to reduce adverse pregnancy events, including reducing preterm birth by more than 50% in a 2023 case-control study. ***** Would this bring value to you, your family or your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

“Deep Dive″ or uncut version of our video podcast. Drs Jeff Brown and Jeff Cole interview Dr. David Kay (CMO) and Gabe Szabo (CEO) or Surgical Targeted Solutions, Inc. Both gentlemen have had enormous success building and operating medical companies. For Dr. Kay, Orthohelix was the first company that he helped form, build and exit. As technology continues to rapidly advance in healthcare, there are times when solutions don’t bring adequate value when compared to the steep learning curves and restrained budgets. As just one example, rather than trying to find ways to use robotic assistance in surgery for an increasing number of things, some of the most impactful potential gains relate to improving process and understanding “why we do what we do”.One example of this is in the surgical treatment of hip fractures. Given the changing population demographics, hip fractures are expected to rise dramatically over the next 10 years, all while the surgeon pool is shrinking. As new surgeons come on board to deal with this exploding volume, there risks a wide range in skill and experience level that make OR staffing very difficult. It’s hard to allocate resources when the same operation can range from 30 minutes to 120 minutes.Has the team at Surgical Targeted Solutions, Inc. found a potential solution for this problem and created a cost-effective, simple tool that provides reliability and reproducibility for improved hip fracture outcomes?The first step in the surgical treatment is placement of a guidewire within a center-head position. This solution changes an unguided first step to one that is computer-assisted and guided so that optimal positioning of the implant can be achieved THE FIRST TIME…EVERY TIME.Compared with robot-assisted procedures, this solution offers affordability, simplicity, adaptability and an easy or quick learning curve. This system can also be used in the training of residents to bring balance between skill and experience levels.The benefits to cost and outcome are significant and include decreased OR time, more predictable procedure length, fewer complications, less radiation and reduction in implant waste or explants.During the FDA process and early commercialization, Surgical Targeted Solution, Inc will be highly focused on the hip fracture market. With that said there are numerous additional adaptations covered under their patent and where solutions and business will be developed.*****Would this bring value to you, your family or your medical practice? Investable merits of this company? Let’s discuss in the forum.If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today!https://mergemedical.community.forum/*****DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

Stated as a matter of fact, cybersecurity is a big f*^&%ing deal.Join us in a Deep Dive version of the Merge Medical podcast as Dr. Jeff Brown and Dr. Jeff Cole interview Dr. Jose Bolanos. Dr. Bolanos is founder and CEO of Nimbus-T Global and offers a compelling opportunity for enterprise and individuals alike to protect themselves in a world full of bad actors.Cybersecurity threats can hit home in so many ways. Unfortunately, the medical profession and healthcare industry seem to be like fish in a barrel. Constant threats, frequent losses...and few, if any, wins.In addition to high profile ransomware attacks such as Change Healthcare and Ascension, there are countless direct attacks on medical practices. One of these attacks can easily bankrupt a successful, long standing medical practice.With billion-dollar market cap companies trying to create meaningful solutions and put a notch in the win column, is it possible that a physician holds the keys to one of the most revolutionary solutions in existence?Moving well beyond two-factor authentication (2FA) and multi-factorial authentication (MFA), Nimbus-T Global / Nimbus-Key ID provides the most advanced cybersecurity protection at login to enterprise systems. The Nimbus-Key ID mobile app registers each user with KYC/AI/Biometric verification. The user logs into the mobile app with True User Verification and the system bypasses passwords with dynamically encrypted ID in a QRcode (DE-MFA). This system protects the enterprise login process and the user’s true access.Also, having experience with poor cooperation across the myriad of software systems required for the day-to-day activities of both office-based and hospital-based physicians, much thought has gone into the time efficiency of the hardware-agnostic process.If you have escaped direct cybersecurity threat or loss up to this point, some experts would say that it’s only a matter of time.Tune in to the latest Merge Medical podcast to learn more.*****Would this bring value to you, your family or your medical practice? Investable merits of this company? Let’s discuss in the forum.If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today!https://mergemedical.community.forum/*****DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

Welcome to the Merge Medical Podcast, where today’s healthcare innovators and leaders come together to shape tomorrow’s healthcare landscape. In our latest episode, we’re honored to host Dr. Robert Pearl, the former CEO of Kaiser Permanente, a prolific author and a visionary in the fields of AI and healthcare. Dr. Robert Pearl was the CEO of The Permanente Medical Group (Kaiser Permanente) from 1999-2017. In this role he led 12,000 physicians, 42,000 staff and was responsible for the nationally recognized medical care of over 5 million Kaiser Permanente members on the west and east coasts. His newest book, “ChatGPT, MD: How AI-Empowered Patients & Doctors Can Take Back Control of American Medicine” debuted as #1 on Amazon’s “New Best Seller” list. All profits from the book go to Doctors Without Borders. He is also the author of “Mistreated: Why We think We’re Getting Good Healthcare—And Why We’re Usually Wrong,” a Washington Post bestseller and “Uncaring: How the Culture of Medicine Kills Doctors and Patients,” published May 2021. Pearl, named one of Modern Healthcare’s 50 most influential physician leaders, serves as a clinical professor of plastic surgery at Stanford University School of Medicine and is on the faculty of the Stanford Graduate School of Business. He hosts the popular podcasts Fixing Healthcare and Medicine: The Truth, publishes a newsletter called Monthly Musings on American Healthcare, and is a regular contributor to Forbes. Dr. Pearl received his medical degree from the Yale University School of Medicine and completed his residency at Stanford University. Connect with Dr. Robert Pearl on Twitter @RobertPearlMD, LinkedIn and at his website robertpearlmd.com.

Welcome to the Merge Medical Podcast, where today's healthcare innovators and leaders come together to shape tomorrow's healthcare landscape. In our latest episode, we're honored to host Dr. Harvey Castro, a visionary ER physician, AI healthcare futurist, and prolific author in the field of AI and healthcare. Dr. Castro delves into how artificial intelligence is revolutionizing patient care and physician practices, sharing his journey in developing AI technologies aimed at improving outcomes and building a sustainable future for healthcare professionals. Discover the potential of AI to transform healthcare delivery, enhance patient experiences, and unlock new avenues for private practice growth and wealth creation.This is a must-listen for anyone passionate about the intersection of healthcare and technology, seeking practical insights and inspiration to navigate the challenges and opportunities ahead. Join us as Dr. Harvey Castro leads the way in leveraging AI for a healthier tomorrow. Merge Medical Website: https://mergemedical.orgLinkedIn Newsletter: https://www.linkedin.com/build-relation/newsletter-follow?entityUrn=7080491988705234946

Beyond being a solid entrant to the DPC (direct primary care space) market, First Primary Care founder, Dr. Geetinder Goyal, and his team are on their way to forming a physician led insurance company that solves for healthcare industry’s terminal illness, the mega-carriers.“10 in 10″ or quick hitting version of our video podcast. Drs Jeff Brown and Jeff Cole interview Dr. Goyal, Founder of First Primary Care.First Primary Care (FPC) grew both its membership and its revenue by more than 100% between 2023 and 2024. The vast majority of the 6000 members have onboarded through self-funded employer plans. These plans are comprised of a vertical stack of solutions designed to optimally benefit the patient, the employer, and the physician care team.While many direct primary care (DPC) businesses are emerging, we are not aware of another DPC company has built a full stack health plan that includes a strong primary care base with integrated partners for cash pay specialists and services, a pharmacy benefit manager, TPAs (third party administrators), PPO network access, stop-loss insurance and distribution through brokers who are becoming more of a benefit advisor.With a focus on price transparency, healthcare can become more stream-lined, and value can be measured. The incentives of the FPC physicians are aligned with that of the patient, health and prevention. The original role of insurance is restored to cover catastrophic issues, and not day-to-day needs.Consistent results show a savings of $200K – $300K for a company with 100 employees. First Primary Care accomplishes this with a tiered service line beginning with a solid foundation of primary care. This base layer represents 65% of care and is free to the patient, without copays or other expenses. Generic prescriptions are free. The second level, 25% of care, is Guided Healthcare and demonstrates price transparency and cash pay by the plan for specialists, imaging, outpatient surgery and more. The final 10% is “Guided to Network” care for hospitalizations, ER visits, or catastrophic events. *****Would this bring value to you, your family or your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ Timestamps:03:40 –A STRONG FOUNDATION06:30 – PRICE TRANSPARENCY06:45 – TIERED APPROACH07:28 – SELF-FUNDED EMPLOYERS08:35 – THE ORIGINAL ROLE OF INSURANCE11:25 – COST SAVINGS TO EMPLOYERS15:20 – COST VS VALUE16:05 – 65% BASE LAYER OF FREE HEALTHCARE17:45 – GUIDED HEALTHCARE19:30 – GUIDED TO NETWORK21:05 – PLAN ADMINISTRATION24:20 – EMPLOYER’S RISK26:55 – STOP-LOSS CLAIM FUND SURPLUS29:55 – WHY NOT REDESIGN INSURANCE?34:30 – STARTING A PHYSICIAN LED INSURANCE COMPANY40:50 – THE CHANGING ROLE OF BROKERS47:18 – TPA (THIRD PARTY ADMINISTRATOR) AS PARTNER48:55 – PHARMACY SERVICES54:30 – TEAM57:25 – RPM (Remote Patient Monitoring)59:45 – WHO IS YOUR CUSTOMER?102:15 – GROWTH / NATIONAL FOOTPRINT103:50 – THE BIG INSURERS: ARE THEY TOO BIG TO FAIL? *****DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice.

Beyond being a solid entrant to the DPC (direct primary care space) market, First Primary Care founder, Dr. Geetinder Goyal, and his team are on their way to forming a physician led insurance company that solves for healthcare industry’s terminal illness, the mega-carriers.“Deep Dive″ or uncut version of our video podcast. Drs Jeff Brown and Jeff Cole interview Dr. Goyal, Founder of First Primary Care.First Primary Care (FPC) grew both its membership and its revenue by more than 100% between 2023 and 2024. The vast majority of the 6000 members have onboarded through self-funded employer plans. These plans are comprised of a vertical stack of solutions designed to optimally benefit the patient, the employer, and the physician care team.While many direct primary care (DPC) businesses are emerging, we are not aware of another DPC company has built a full stack health plan that includes a strong primary care base with integrated partners for cash pay specialists and services, a pharmacy benefit manager, TPAs (third party administrators), PPO network access, stop-loss insurance and distribution through brokers who are becoming more of a benefit advisor.With a focus on price transparency, healthcare can become more stream-lined, and value can be measured. The incentives of the FPC physicians are aligned with that of the patient, health and prevention. The original role of insurance is restored to cover catastrophic issues, and not day-to-day needs.Consistent results show a savings of $200K – $300K for a company with 100 employees. First Primary Care accomplishes this with a tiered service line beginning with a solid foundation of primary care. This base layer represents 65% of care and is free to the patient, without copays or other expenses. Generic prescriptions are free. The second level, 25% of care, is Guided Healthcare and demonstrates price transparency and cash pay by the plan for specialists, imaging, outpatient surgery and more. The final 10% is “Guided to Network” care for hospitalizations, ER visits, or catastrophic events. *****Would this bring value to you, your family or your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number,you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ Timestamps:03:40 –A STRONG FOUNDATION06:30 – PRICE TRANSPARENCY06:45 – TIERED APPROACH07:28 – SELF-FUNDED EMPLOYERS08:35 – THE ORIGINAL ROLE OF INSURANCE11:25 – COST SAVINGS TO EMPLOYERS15:20 – COST VS VALUE16:05 – 65% BASE LAYER OF FREE HEALTHCARE17:45 – GUIDED HEALTHCARE19:30 – GUIDED TO NETWORK21:05 – PLAN ADMINISTRATION24:20 – EMPLOYER’S RISK26:55 – STOP-LOSS CLAIM FUND SURPLUS29:55 – WHY NOT REDESIGN INSURANCE?34:30 – STARTING A PHYSICIAN LED INSURANCE COMPANY40:50 – THE CHANGING ROLE OF BROKERS47:18 – TPA (THIRD PARTY ADMINISTRATOR) AS PARTNER48:55 – PHARMACY SERVICES54:30 – TEAM57:25 – RPM (Remote Patient Monitoring)59:45 – WHO IS YOUR CUSTOMER?102:15 – GROWTH / NATIONAL FOOTPRINT103:50 – THE BIG INSURERS: ARE THEY TOO BIG TO FAIL? *****DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice.

Healthcare has been criticized for its slow adoption of advanced technology, and independent doctors can lag even further behind the curve due to the reasonable fear of the financial, security, and administrative risks associated with implementing new and unproven technologies such as AI, digital therapeutics, and remote vital sign monitoring. The healthcare technology landscape is littered with vendors who don’t always have the physician or patient best-interest in mind.“10 in 10” or quick-hitting version of our video podcast. Drs Jeff Brown and Jeff Cole interview Dr. Brittany Busse, Co-Founder of ViTel Health.ViTel Health is a technology platform-as-a-service company that is empowering physicians to thrive in independent practice by creating and vetting technology solutions that are proven to improve the lives of physicians and the patients they in their care. ViTel Health was founded by Dr. Brittany Busse and Doug Sumaraga in 2021 with the mission “Happy Physicians, Healthy Patients.” Our current “sick care” system has taken the autonomy of physicians, left us burned out, and has decimated the care of patients. ViTel Health is using technology to turn the sick care system to healthcare system and partnering physicians with health coaches who can offer consistent support to patients struggling with chronic disease. It’s more than Remote Physiologic Monitoring, it’s Tech Enabled Health Coaching, and it gets results.Patients are healthier, staying out of the hospital, and physician practices are thriving with the extra revenue combined with limited administrative work. ViTel Health has created a simple vertically-integrated solutions that handles all of the compliance, hiring, documentation, and billing associated with this billable service, empowering doctors to take better care of patients and earn extra revenue.Beyond cutting edge RPM/CCM services, ViTel Health and the ViTel Health Physician Services Cooperative are committed to empowering the return of the independent physician practice in the US. Our services include an affordable and flexible EHR, cost effective credentialing/contracting, revenue cycle management, malpractice, legal advice, and more.*****Would this bring value to you, your family or your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion.Sign up today! https://mergemedical.community.forum/***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

Healthcare has been criticized for its slow adoption of advanced technology, and independent doctors can lag even further behind the curve due to the reasonable fear of the financial, security, and administrative risks associated with implementing new and unproven technologies such as AI, digital therapeutics, and remote vital sign monitoring. The healthcare technology landscape is littered with vendors who don’t always have the physician or patient best-interest in mind. “10 in 10” or quick-hitting version of our video podcast. Drs Jeff Brown and Jeff Cole interview Dr. Brittany Busse, Co-Founder of ViTel Health. ViTel Health is a technology platform-as-a-service company that is empowering physicians to thrive in independent practice by creating and vetting technology solutions that are proven to improve the lives of physicians and the patients they in their care. ViTel Health was founded by Dr. Brittany Busse and Doug Sumaraga in 2021 with the mission “Happy Physicians, Healthy Patients.” Our current “sick care” system has taken the autonomy of physicians, left us burned out, and has decimated the care of patients. ViTel Health is using technology to turn the sick care system to healthcare system and partnering physicians with health coaches who can offer consistent support to patients struggling with chronic disease. It’s more than Remote Physiologic Monitoring, it’s Tech Enabled Health Coaching, and it gets results. Patients are healthier, staying out of the hospital, and physician practices are thriving with the extra revenue combined with limited administrative work. ViTel Health has created a simple vertically-integrated solutions that handles all of the compliance, hiring, documentation, and billing associated with this billable service, empowering doctors to take better care of patients and earn extra revenue. Beyond cutting edge RPM/CCM services, ViTel Health and the ViTel Health Physician Services Cooperative are committed to empowering the return of the independent physician practice in the US. Our services include an affordable and flexible EHR, cost effective credentialing/contracting, revenue cycle management, malpractice, legal advice, and more. ***** Would this bring value to you, your family or your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

Loss of autonomy is one of the strongest factors leading to physician burnout and exits from medicine. Are you ready to practice on your own schedule? Interested in a cost-effective hybrid practice with a mix of in-person and virtual patient care visits? Satellite offices? Reality check…long term leasing of real estate makes this impossible. “Deep Dive” or uncut version of our video podcast. Drs Jeff Brown and Jeff Cole interview Dr. Greg Goldmacher (Co-Founder) and Ronak Vyas (CEO) of MedCoShare.   MedCoShare is combining co-working space with additional services within a fully scalable membership model that starts with one half day per week and a one-month commitment. Premium support services include ordering of supplies, office staffing and practice marketing. MedCoShare plans to make additional bolt-on services available in 2024-25. These targeted services include billing, revenue cycle management, credentialing, and more. Whether you are part of a sizable group or in solo practice, the MedCoShare membership model makes practicing the way you like a reality. It makes opening a satellite office (or two) cost-effective. MedCoShare has moved well beyond the proof-of-concept stage and has its eye on a national growth strategy. This innovative, flexible, and affordable co-working model is currently available in Pennsylvania and New Jersey. Fresh, modern spaces are planned for more locations on the East Coast, as well as other parts of the US in 2024-25. *****Would this bring value to you, your family or your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion.Sign up today! https://mergemedical.community.forum/*****DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

Loss of autonomy is one of the strongest factors leading to physician burnout and exits from medicine. Are you ready to practice on your own schedule? Interested in a cost-effective hybrid practice with a mix of in-person and virtual patient care visits? Satellite offices? Reality check…long term leasing of real estate makes this impossible. “Deep Dive” or uncut version of our video podcast. Drs Jeff Brown and Jeff Cole interview Dr. Greg Goldmacher (Co-Founder) and Ronak Vyas (CEO) of MedCoShare.   MedCoShare is combining co-working space with additional services within a fully scalable membership model that starts with one half day per week and a one-month commitment. Premium support services include ordering of supplies, office staffing and practice marketing. MedCoShare plans to make additional bolt-on services available in 2024-25. These targeted services include billing, revenue cycle management, credentialing, and more. Whether you are part of a sizable group or in solo practice, the MedCoShare membership model makes practicing the way you like a reality. It makes opening a satellite office (or two) cost-effective. MedCoShare has moved well beyond the proof-of-concept stage and has its eye on a national growth strategy. This innovative, flexible, and affordable co-working model is currently available in Pennsylvania and New Jersey. Fresh, modern spaces are planned for more locations on the East Coast, as well as other parts of the US in 2024-25. *****Would this bring value to you, your family or your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion.Sign up today! https://mergemedical.community.forum/*****DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

Sleep is a wonderful thing…if, and when, you can count on it. The sleep aid business is projected to reach $118B by 2030. Why? Very few things treat the root cause. Will Lumos revolutionize the sleep industry through the ability to strengthen and modulate circadian rhythms, the foundation of sleep?“10 in 10” or quick-hitting version of our video podcast. Drs Jeff Brown and Jeff Cole interview Biquan Luo, Ph.D. (CEO and Co-Founder) and Kyle Pfaffenbach, Ph.D. (Performance Nutrition Specialist) of Lumos. Lumos was founded by Stanford scientists specializing in regulating human circadian rhythms, Lumos offers a sleep solution for everyone via its smart sleep mask, cell phone app and patented technology. The positive effects of science-based algorithms for jet lag, sleep disruptions caused by night shifts and everyday falling asleep and staying asleep have been demonstrated by robust clinical studies funded by the US military.Lumos is poised to significantly impact quality of sleep on a large scale with its low COG, cost-effective solution. Might you want to own a small piece of this company whose science is two decades in the making?*****Would this bring value to you, your family or your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion.Sign up today! https://mergemedical.community.forum/*****DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

Sleep is a wonderful thing…if, and when, you can count on it. The sleep aid business is projected to reach $118B by 2030. Why? Very few things treat the root cause. Will Lumos revolutionize the sleep industry through the ability to strengthen and modulate circadian rhythms, the foundation of sleep?“Deep Dive” or uncut version of our video podcast. Drs Jeff Brown and Jeff Cole interview Biquan Luo, Ph.D. (CEO and Co-Founder) and Kyle Pfaffenbach, Ph.D. (Performance Nutrition Specialist) of Lumos. Lumos was founded by Stanford scientists specializing in regulating human circadian rhythms, Lumos offers a sleep solution for everyone via its smart sleep mask, cell phone app and patented technology. The positive effects of science-based algorithms for jet lag, sleep disruptions caused by night shifts and everyday falling asleep and staying asleep have been demonstrated by robust clinical studies funded by the US military.Lumos is poised to significantly impact quality of sleep on a large scale with its low COG, cost-effective solution. Might you want to own a small piece of this company whose science is two decades in the making?*****Would this bring value to you, your family or your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion.Sign up today! https://mergemedical.community.forum/*****DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.​

A WalMart type POS technology solution for the multi-billion dollar surgical industry. The Summate Trakker is the first & only scanning solution for ALL products used during a surgery, from both inside and outside the sterile field. Handwritten notes are still the norm?“10 in 10” or quick hitting version of our video podcast. Drs Jeff Brown and Jeff Cole interview Phil Sayles, Founder and CEO of Summate Technologies. Summate has developed the Trakker™, a revolutionary POU tracking platform that leverages patented microchip tagging technology and workflow-friendly software. The Trakker is the first and only total consumption scanning solution for ALL products used during a surgical procedure, at the true point of use, from both inside and at the edge of the sterile field. The platform also delivers product intelligence and VOIP communication to field staff as well. It deploys two types of highly unique scanning technology.*****Would this bring value to your medical practice, outpatient surgical center or hospital? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion.Sign up today! https://mergemedical.community.forum/*****DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

By going back to the drawing board, has this global team of founders solved for tricuspid regurgitation, the “forgotten valve”? How far will they advance this breakthrough solution before one of the 4 major cardiovascular giants want to own it?“10 in 10” or quick-hitting version of our video podcast. Drs Jeff Brown and Jeff Cole interview Frank Ahmann of Triflo Cardiovascular.Tricuspid regurgitation (TR) affects millions of elderly patients and is associated with a significant decrease of quality of life, increased hospitalizations, and impaired survival. Symptomatic severe TR is grossly under-treated. The current leading transcatheter technologies only address a limited segment of the patient population.Southern California - based Triflo Cardiovascular is developing the Tricuspid Flow Optimizer, a minimally invasive valve specifically ideated for TR. The minimalistic design includes an adaptive mini valve and single size transfemoral delivery system. The Optimizer works in tandem with the native valve regardless of its size and shape therefore treating a broader patient population.First successful clinical cases have been completed indicating that the device not only reduces regurgitation, but also supports the global cardiac recovery to improve function, exercise capacity, and quality of life. Triflo Cardiovascular is gearing up to expand clinical studies and move towards future regulatory approval. They are preparing to raise a Series B round of funding.*****Would this bring value to your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion.Sign up today! https://mergemedical.community.forum/*****DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

Can this patented Class I FDA Device featuring a reusable blade and reusable handle make intubation easier, faster, and safer in even the most difficult patients and most challenging environments?“Deep Dive” or uncut version of our video podcast. Drs Jeff Brown and Jeff Cole interview the founders of IntuScope, Charla and Keith Bartozzi. IntuScope was founded to pursue and commercialize a new approach to advance field and clinical intubation techniques, reduce the skill disparity, and improve patient outcomes. IntuScope is a patented Class I FDA Device featuring a reusable blade and reusable handle that utilizes a patient’s own anatomy and two actuating arms to open the airway. IntuScope makes intubation easier, faster, and safer in even the most difficult patients. While the device can be used for any intubation, the initial efforts will be focused on the pre-hospital market.*****Would this bring value to your practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion.Sign up today! https://mergemedical.community.forum/*****DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

Ketones are the most pure form of energy that our body makes. Have these former Coca-Cola executives and the original founder created the ultimate multifunctional energy and health drink?“10 in 10” or quick-hitting version of our video podcast. Drs Jeff Brown and Jeff Cole interview Udaiyan Jatar (Co-Founder & CEO) and Joseph Motto (President & CFO) of Tecton.Tecton is a multifunctional health drink that is based on a breakthrough in exogenous ketone science. Its proprietary ketone molecule overcomes all the biggest barriers to mainstream adoption of exogenous ketones. It tastes good, it is safe even at very high doses (80-100 per day) for all age groups, and it is affordable. The product was designed to be completely safe and healthy with zero carbs, zero caffeine and it is clean label. This allows Tecton to be consumed for metabolic health at macronutrient levels, and therefore, serves as a foundation for weight management, brain health and physical performance.*****Would this bring value to your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion.Sign up today! https://mergemedical.community.forum/*****DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.*****

By going back to the drawing board, has this global team of founders solved for tricuspid regurgitation, the “forgotten valve”? How far will they advance this breakthrough solution before one of the 4 major cardiovascular giants want to own it?“Deep Dive” or uncut version of our video podcast. Drs Jeff Brown and Jeff Cole interview Frank Ahmann of Triflo Cardiovascular.Tricuspid regurgitation (TR) affects millions of elderly patients and is associated with a significant decrease of quality of life, increased hospitalizations, and impaired survival. Symptomatic severe TR is grossly under-treated. The current leading transcatheter technologies only address a limited segment of the patient population.Southern California - based Triflo Cardiovascular is developing the Tricuspid Flow Optimizer, a minimally invasive valve specifically ideated for TR. The minimalistic design includes an adaptive mini valve and single size transfemoral delivery system. The Optimizer works in tandem with the native valve regardless of its size and shape therefore treating a broader patient population.First successful clinical cases have been completed indicating that the device not only reduces regurgitation, but also supports the global cardiac recovery to improve function, exercise capacity, and quality of life. Triflo Cardiovascular is gearing up to expand clinical studies and move towards future regulatory approval. They are preparing to raise a Series B round of funding.*****Would this bring value to your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion.Sign up today! https://mergemedical.community.forum/*****DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

Is surgical drain management worthy of disruption? SOMAVAC is launching a deep tissue negative pressure device for large flaps (mastectomies and hernia repairs). FDA cleared for seroma prevention. Benefits to the patient & hospital/payor undeniable?“Deep Dive” or uncut version of our video podcast. Drs Jeff Brown and Jeff Cole interview Esra Roan, PhD and Jane Berz, RN, MSN of SOMAVAC, an early-revenue company launching a deep tissue Negative Pressure Therapy device for large flaps created by plastic and general surgeries such as mastectomies and hernia repairs. The internationally patented SOMAVAC SVS delivers constant negative pressure therapy to effectively remove fluids and hold tissue layers together. The device is FDA cleared for seroma prevention. Early studies indicate earlier removal of surgical drains, which is known to correlate with infection rates, and overall fewer complications when compared to literature. The system is closed with one-click fluid disposal bags and markings eliminating the need to pour fluid in to measuring cup. SOMAVAC helps patients and their families recover with dignity after life-impacting surgeries.Significant savings to the hospital and health systems is projected within the immediate $550M market and $4.5B US addressable market. The closed system of fluid collection also allows SOMAVAC to crossover from the medtech to the biotech space potentially advancing science through the analysis of the seroma fluid collected postoperatively from the surgical site. This also extends the total addressable market to $15B.*****Would this bring value to your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion.Sign up today! https://mergemedical.community.forum/*****DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

Is surgical drain management worthy of disruption? SOMAVAC is launching a deep tissue negative pressure device for large flaps (mastectomies and hernia repairs). FDA cleared for seroma prevention. Benefits to the patient & hospital/payor undeniable?“10 in 10” or quick hitting version of our video podcast. Drs Jeff Brown and Jeff Cole interview Esra Roan, PhD and Jane Berz, RN, MSN of SOMAVAC, an early-revenue company launching a deep tissue Negative Pressure Therapy device for large flaps created by plastic and general surgeries such as mastectomies and hernia repairs. The internationally patented SOMAVAC SVS delivers constant negative pressure therapy to effectively remove fluids and hold tissue layers together. The device is FDA cleared for seroma prevention. Early studies indicate earlier removal of surgical drains, which is known to correlate with infection rates, and overall fewer complications when compared to literature. The system is closed with one-click fluid disposal bags and markings eliminating the need to pour fluid in to measuring cup. SOMAVAC helps patients and their families recover with dignity after life-impacting surgeries.Significant savings to the hospital and health systems is projected within the immediate $550M market and $4.5B US addressable market. The closed system of fluid collection also allows SOMAVAC to crossover from the medtech to the biotech space potentially advancing science through the analysis of the seroma fluid collected postoperatively from the surgical site. This also extends the total addressable market to $15B.*****Would this bring value to your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion.Sign up today! https://mergemedical.community.forum/*****DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

If the NIH and JDRF have given Diatech Diabetes the nod through funding…should this company be on your radar? SmartFusion™ is an infusion set failure detection system licensed as a SaaS algorithm to infusion device manufacturers.“Deep Dive” or uncut version of our video podcast. Drs Jeff Brown and Jeff Cole interview Diatech Diabetes founders John Wilcox and Luis Blanco. Diatech Diabetes is a medical device company committed to changing the way infusion set failure detection is done with their infusion set failure detection system, SmartFusion™. This is accomplished with a combination of real time data analysis and machine learning.SmartFusion™, is an infusion set failure detection system licensed as software-as-a-service to infusion device manufacturers. SmartFusion™ is an algorithm designed specifically for insulin (and other ambulatory drug delivery) pumps to detect different types of infusion failures not currently detected by insulin pumps on the market.*****Would this bring value to your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion.Sign up today! https://mergemedical.community.forum/*****DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

If the NIH and JDRF have given Diatech Diabetes the nod through funding…should this company be on your radar? SmartFusion™ is an infusion set failure detection system licensed as a SaaS algorithm to infusion device manufacturers.“10 in 10” or quick hitting version of our video podcast. Drs Jeff Brown and Jeff Cole interview Diatech Diabetes founders John Wilcox and Luis Blanco. Diatech Diabetes is a medical device company committed to changing the way infusion set failure detection is done with their infusion set failure detection system, SmartFusion™. This is accomplished with a combination of real time data analysis and machine learning.SmartFusion™, is an infusion set failure detection system licensed as software-as-a-service to infusion device manufacturers. SmartFusion™ is an algorithm designed specifically for insulin (and other ambulatory drug delivery) pumps to detect different types of infusion failures not currently detected by insulin pumps on the market.*****Would this bring value to your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion.Sign up today! https://mergemedical.community.forum/*****DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

A WalMart type POS technology solution for the multi-billion dollar surgical industry. The Summate Trakker is the first & only scanning solution for ALL products used during a surgery, from both inside and outside the sterile field. Handwritten notes are still the norm?“Deep Dive” or uncut version of our video podcast. Drs Jeff Brown and Jeff Cole interview Phil Sayles, Founder and CEO of Summate Technologies. Summate has developed the Trakker™, a revolutionary POU tracking platform that leverages patented microchip tagging technology and workflow-friendly software. The Trakker is the first and only total consumption scanning solution for ALL products used during a surgical procedure, at the true point of use, from both inside and at the edge of the sterile field. The platform also delivers product intelligence and VOIP communication to field staff as well. It deploys two types of highly unique scanning technology.*****Would this bring value to your medical practice, outpatient surgical center or hospital? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion.Sign up today! https://mergemedical.community.forum/*****DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

With all of the modern day advances, the fax still lives on. The Medsender platform integrates with EMR/EHR systems applying AI, process automation and task management to incoming faxes and medical records.“Deep Dive” or uncut version of our video podcast. Drs Jeff Brown and Jeff Cole interview Salman Haque, one of 3 co-founders of Medsender. Medsender is a startup on a mission to automate healthcare administration. The Medsender platform integrates with electronic health record (EHR) systems and applies artificial intelligence and robotic process automation to enable medical practices to automate document workflows, such as filing incoming faxes, creating new patient charts, and assigning tasks in the EHR.*****Would this bring value to your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion.Sign up today! https://mergemedical.community.forum/*****DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

With all of the modern day advances, the fax still lives on. The Medsender platform integrates with EMR/EHR systems applying AI, process automation and task management to incoming faxes and medical records.“10 in 10” or quick hitting version of our video podcast. Drs Jeff Brown and Jeff Cole interview Salman Haque, one of 3 co-founders of Medsender. Medsender is a startup on a mission to automate healthcare administration. The Medsender platform integrates with electronic health record (EHR) systems and applies artificial intelligence and robotic process automation to enable medical practices to automate document workflows, such as filing incoming faxes, creating new patient charts, and assigning tasks in the EHR.*****Would this bring value to your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion.Sign up today! https://mergemedical.community.forum/*****DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

Merge Medical is proud to call VitaTek (formerly Vita Group) a partner and to offer their knowledge and capabilities to our community.VitaTek is a medical device incubator with vertical integration servicing every step from idea vetting to sales. More specifically, this includes in house R&D, prototyping, regulatory work, user testing, DFM, die mold creation, manufacturing, sterilization, distribution, and sales team access.Through growth and strategic acquisitions, VitaTek is largest private medical device manufacturer in the state of Minnesota with 150,000 sq-ft. Vita Group owns 11 medical device products; 4 are FDA approved and currently on the market. Four more devices will enter the market in 2024.*****Would VitaTek bring value to your medical practice or personal innovative efforts? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion.Sign up today! https://mergemedical.community.forum/*****DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

MiCare Path is building a closer connection with an ever-growing population through its mobile health platform. Can personalized patient education and data-driven decisions result in better patient outcomes across multiple subspecialties?“Deep Dive” or uncut version of our video podcast. Drs Jeff Brown and Jeff Cole interview Scott Laster, one of 3 co-founders of MiCare Path. MiCare Path is building a closer connection with an ever-growing patient population, MiCare Path is a reimbursable integrated mobile health platform delivering improved outcomes with data-driven decisions, personalized patient education and care paths promoting clinical efficiencies for a better patient experience.*****Would this bring value to your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion.Sign up today! https://mergemedical.community.forum/*****DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

MiCare Path is building a closer connection with an ever-growing population through its mobile health platform. Can personalized patient education and data-driven decisions result in better patient outcomes across multiple subspecialties?“10 in 10” or quick hitting version of our video podcast. Drs Jeff Brown and Jeff Cole interview Scott Laster, one of 3 co-founders of MiCare Path. MiCare Path is building a closer connection with an ever-growing patient population, MiCare Path is a reimbursable integrated mobile health platform delivering improved outcomes with data-driven decisions, personalized patient education and care paths promoting clinical efficiencies for a better patient experience.*****Would this bring value to your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion.Sign up today! https://mergemedical.community.forum/*****DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

With an open rate of 99%, there simply isn’t a better form of Healthcare communication than texting. This multi-patented secure and HIPAA-compliant solution services 13 million patients with AI-driven team-based workflows and EMR/EHR integration.“Deep Dive” or uncut version of our video podcast. Drs Jeff Brown and Jeff Cole interview the founder of Rhinogram. Rhinogram’s complete digital communications and virtual care solution empowers healthcare facilities and their patients with the ability to initiate direct SMS/MMS HIPAA-compliant & secure text message communications across the full patient journey. Rhinogram was founded in 2015 by practicing orthodontist, Dr. Keith Dressler, with a vision to revolutionize how patients access care. Rhinogram serves over 13M patients in over 50+ healthcare specialties. Their mission is to provide equal access to care through simple, direct and reliable market leading patented technology.*****Would this bring value to your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion.Sign up today! https://mergemedical.community.forum/*****DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

With an open rate of 99%, there simply isn’t a better form of Healthcare communication than texting. This multi-patented secure and HIPAA-compliant solution services 13 million patients with AI-driven team-based workflows and EMR/EHR integration.“10 in 10” or quick hitting version of our video podcast. Drs Jeff Brown and Jeff Cole interview the founder of Rhinogram. Rhinogram’s complete digital communications and virtual care solution empowers healthcare facilities and their patients with the ability to initiate direct SMS/MMS HIPAA-compliant & secure text message communications across the full patient journey. Rhinogram was founded in 2015 by practicing orthodontist, Dr. Keith Dressler, with a vision to revolutionize how patients access care. Rhinogram serves over 13M patients in over 50+ healthcare specialties. Their mission is to provide equal access to care through simple, direct and reliable market leading patented technology.*****Would this bring value to your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion.Sign up today! https://mergemedical.community.forum/*****DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

Can acoustic biomarkers and AI be used to identify entry into disease state transition zones early enough to allow proactive decision making? Predict an ileus multiple days before it happens? Applications for cardiac and pulmonary disorders?“Deep Dive” or uncut version of our video podcast. Drs Jeff Brown and Jeff Cole interview the founders of Entac Medical. Entac Medical is a digital health company developing wearable devices. Their technology applies predictive analytics/AI to biological acoustic signals to predict downstream patient adverse events, improving patient outcomes, preventing hospital readmissions and reducing the cost of care.More specifically, they are using acoustic biomarkers to identify entry into disease state transition zones early enough to allow proactive decision making. In the treatment of post-operative ileus, this technology can significantly impact morbidity and mortality while also saving hospitals millions. Through an AI development platform, similar impact in cardiac and pulmonary disease states is hopeful.*****Would this bring value to your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion.Sign up today! https://mergemedical.community.forum/*****DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

Can this patented Class I FDA Device featuring a reusable blade and reusable handle make intubation easier, faster, and safer in even the most difficult patients and most challenging environments?“10 in 10” or quick-hitting version of our video podcast. Drs Jeff Brown and Jeff Cole interview the founders of Intuscope, Charla and Keith Bartozzi.. IntuScope was founded to pursue and commercialize a new approach to advance field and clinical intubation techniques, reduce the skill disparity, and improve patient outcomes. IntuScope is a patented Class I FDA Device featuring a reusable blade and reusable handle that utilizes a patient’s own anatomy and two actuating arms to open the airway. IntuScope makes intubation easier, faster, and safer in even the most difficult patients. While the device can be used for any intubation, the initial efforts will be focused on the pre-hospital market.*****Would this bring value to your practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion.Sign up today! https://mergemedical.community.forum/*****DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

With a market cap of several hundred million, to call DiscGenics a “Startup” isn’t exactly true. This growth stage company has their eye on becoming a blockbuster (injectable) drug company. Can a new cell line (discogenic cells) revolutionize the way that spinal disc disease is treated and regenerate a failing disc?“Deep Dive” or uncut version of our video podcast. Drs Jeff Brown and Jeff Cole interview the founders of DiscGenics. DiscGenics is committed to revolutionizing the way millions of patients suffering from chronic back pain will be treated through a focus on developing regenerative therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. They are engineering highly specialized therapeutic progenitor cells (Discogenic Cells) that uniquely address the complex environment of the degenerated disc. DiscGenics’ first product candidate, IDCT (rebonuputemcel), is a regenerative solution; an allogeneic, injectable (non-surgical) cell therapy that utilizes proprietary Discogenic Cells to treat mild to moderate adult lumbar disc degeneration.*****Would this bring value to your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion.Sign up today! https://mergemedical.community.forum/*****DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

With a market cap of several hundred million, to call DiscGenics a “Startup” isn’t exactly true. This growth stage company has their eye on becoming a blockbuster (injectable) drug company. Can a new cell line (discogenic cells) revolutionize the way that spinal disc disease is treated and regenerate a failing disc?“10 in 10” or quick-hitting version of our video podcast. Drs Jeff Brown and Jeff Cole interview the founders of DiscGenics. DiscGenics is committed to revolutionizing the way millions of patients suffering from chronic back pain will be treated through a focus on developing regenerative therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. They are engineering highly specialized therapeutic progenitor cells (Discogenic Cells) that uniquely address the complex environment of the degenerated disc. DiscGenics’ first product candidate, IDCT (rebonuputemcel), is a regenerative solution; an allogeneic, injectable (non-surgical) cell therapy that utilizes proprietary Discogenic Cells to treat mild to moderate adult lumbar disc degeneration.*****Would this bring value to your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion.Sign up today! https://mergemedical.community.forum/*****DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.